Background--Little is known about the association of atrial fibrillation symptom burden with quality of life and outcomes.
1
The European Heart Rhythm Association (EHRA) score has been suggested to assess symptom quality and the impairment in everyday activities caused by arrhythmia-related symptoms. The score evaluates 6 symptom dimensions (palpitations, fatigue, dizziness, dyspnea, chest pain, and anxiety) in 4 severities, ranging from none to symptom frequency that leads to a discontinuation of daily activities. Such a score was encouraged as a simple, but relatively specific, quantification of AF-related symptoms that permits the assessment of functional impairment attributable to AF. 2, 3 It may serve as a measure of quality of life (QoL) and of the limitations in everyday activities. It was validated as a useful semiquantitative classification of health status and as an indicator of health utility in a monocentric study in a specialized clinic. 4 To date, the EHRA score has not been related to AF-related interventions and meaningful outcomes in large cohorts. In asymptomatic patients with AF, mortality during 1 year appeared to be higher compared with individuals with symptomatic AF. 5 In AF outpatients, EHRA score category ≥2 was related to more frequent hospitalizations and possibly higher bleeding risk. 6 Whether AF-related symptom burden, reflected by the EHRA never, occasional (less than once per month), intermediate (once per month to almost daily), and frequent (at least daily).
The maximum category of any of the 6 individual symptoms resulted in the EHRA score. If information on any of the EHRA symptom dimensions was missing at baseline, patients were excluded, leaving 6196 individuals for the analysis. We further assessed QoL by validated questionnaires on preference-based measures of health. The EQ-5D-5L provides preference-based health-related utility to assess costeffectiveness. 8 The Perception of Anti-Coagulant Treatment Questionnaire (PACT-Q) was specifically designed to quantify expectations and treatment satisfaction with oral anticoagulation. 9 Sample items of both questionnaires are provided in Tables S1 and S2 .
Interventions and outcomes
We collected information on pharmacological or electrical cardioversion attempts during follow-up, as well as catheterbased ablation therapy. As outcomes, we assessed the presence of sinus rhythm on the follow-up ECG and adequate heart rate control. The latter was defined as a heart rate between 60 and 100 beats per minute during the clinic visit. Disease outcomes were ischemic stroke/transient ischemic attack/arterial embolism, coronary events (acute coronary syndrome/coronary revascularization), heart failure, and major bleeding. Heart failure was defined as a physician-diagnosed condition or reduced left ventricular ejection fraction. Major bleeding comprised cerebrovascular bleeding and major gastrointestinal or other bleeding events usually requiring blood transfusion.
Statistical Analyses
From 7243 patients, 831 (11.5%) did not have a follow-up visit. Therefore, the data analysis was performed with
Clinical Perspective
What Is New?
• Most patients with atrial fibrillation are symptomatic (>90%), and the symptom burden slightly decreases during 1 year of follow-up.
• The European Heart Rhythm Association symptoms score and its components are moderately related to quality of life, health care use, and cardiovascular outcomes.
• Palpitations are predictive of interventions (cardioversion and ablation therapy) to restore sinus rhythm.
What Are the Clinical Implications?
• Compared with other European Heart Rhythm Association symptoms, palpitations appear to be strong triggers of interventions to restore and maintain sinus rhythm.
complete EHRA score information at baseline and follow-up in 6196 patients. At baseline, 2.98% of the patients had missing values. To determine the assumption of missing completely at random, we compared the baseline characteristics of the individuals used for the analyses and the patients excluded from the analyses. We did not observe significant differences in the distribution of baseline variables (Table S3) . Variables are presented as meanAESD for continuous variables and number (percentage) for discrete variables. In a multivariable stepwise selection model, we calculated b estimates and F values in relation to the EHRA score.
To understand correlations with other metrics of QoL, Spearman rank correlation coefficients for the EHRA score and its components with EQ-5D-5L and PACT-Q items were calculated.
We examined symptom stability over 1 year comparing the proportion of individuals in each EHRA symptom category at baseline and follow-up by the McNemar test. We tested for interactions by cardioversion or ablation therapy during follow-up.
We performed multiple logistic regression models for the EHRA score as a categorical variable and for each symptom dimension separately using ANCOVA across categories in relation to interventions and adverse cardiovascular events. Because of small numbers in the EHRA score categories 1 and 4, we also dichotomized the EHRA score into class 3/4 versus 1/2. Odds ratios (ORs) for the different EHRA classes compared with EHRA score 1 are provided in the Supplemental Material. We chose outcomes on the basis of end points suggested in the literature. 1 Interventions included cardioversions (pharmacological and electrical cardioversion) and catheter-based ablation (pulmonary vein isolation). Major dichotomous adverse cardiovascular outcomes were ischemic stroke/transient ischemic attack/arterial thromboembolic events, coronary events (acute coronary syndrome, including myocardial infarction and unstable angina pectoris, and coronary revascularization), heart failure, and major bleeding. We adjusted for age, sex, and country. In a second model, we additionally adjusted for body mass index, systolic blood pressure/hypertension, diabetes mellitus, current smoking, heart failure, and myocardial infarction. The model examining incident heart failure excluded individuals with heart failure at baseline (N=1723) and patients with missing information about heart failure at baseline (N=165). We chose predictors and potential confounding variables because they have been related to symptoms, disease severity, and outcomes (Data S1).
For adjusted analyses, we used multivariable logistic regression model fitted via the SAS procedure logistic. We calculated P values derived by bootstrapping for the clinical variables to assess the predictive accuracy (Table S4) . We also analyzed the area under the curves from resubstitution and from 10-fold cross validation for the following: (1) the whole model and the EHRA components and (2) the partial model and the EHRA components provided in Tables S5 and  S6. For all the analyses, we used SAS software, version 9.4 (SAS Institute, Cary, NC). A 2-tailed threshold of 0.05 was chosen to indicate statistical significance. Our analyses are exploratory in nature.
Results

Baseline Characteristics
Baseline characteristics of the sample are provided in Table 1 . The mean age was 72 years, and %40% were women. Patients showed a substantial cardiovascular risk factor burden and a high prevalence of cardiovascular disease, with %10% previous myocardial infarction, %30% prevalent heart failure, and 15% previous stroke/transient ischemic attack/other ischemic-thromboembolic events. Most patients were symptomatic; 92% indicated an EHRA score ≥2. The characteristics of individuals excluded because of missing EHRA score information are shown in Table S7 . Strongest clinical correlates of the EHRA score selected from clinical variables in the baseline table were heart failure and female sex. Furthermore, ever smoking, a history of cardioversion and/or ablation, body mass index, and, with smaller estimates, diabetes mellitus and a history of myocardial infarction were selected ( Table 2) . Ten-fold cross-validation P values showed comparable results (Table S4) .
Correlations With Other Metrics of QoL
Although correlations between EHRA score and its components with EQ-5D-5L achieved statistical significance for most bivariate correlations, the strength was moderate ( Table 3) . The highest Spearman correlation coefficient was observed between EHRA score and the ability to perform usual activities (r s =0.308, P<0.0001). The maximum correlation for components of the EHRA score was seen for dyspnea and usual activities (r s =0.339, P<0.0001).
Spearman correlation coefficients of the EHRA score and PACT-Q items are shown in Table S8 . Despite statistical significance, the correlations were weak.
Symptom Development Over Time
In the Figure, we show the proportion of EHRA symptom severity for the 6 dimensions on enrollment and after 1 year. Fatigue was most frequently reported. Only 26.4% of patients at baseline and 32.1% at follow-up never had symptoms of fatigue. The least frequent symptom of the 6 symptoms of the EHRA score was chest pain, which was never experienced by 70.5% of patients at baseline and 77.6% of patients at followup. Most individuals (92%) experienced at least 1 symptom. Over 1 year, symptom severity appeared to improve for all EHRA dimensions (P<0.001). The largest reduction in symptom frequency was observed for palpitations. The highest symptom stability (ie, patients staying in the same category at baseline and follow-up) was seen for chest pain (72.8%), dizziness (61.5%), and anxiety (57.7%). These last 3 symptom dimensions did not show significant interactions with cardioversion or ablation therapy. The EHRA score, palpitations, fatigue, and dyspnea showed statistically significant interactions by cardioversion and ablation therapy, with a larger improvement when these interventions were performed successfully, even after adjustment for antiarrhythmic drug use. Results for the unadjusted model are provided in Table S9 .
EHRA Score Symptoms and Interventions
In Table 4 , we provide risk factor-adjusted logistic regression analyses for EHRA score and EHRA symptom dimensions separately in relation to interventions to restore sinus rhythm for EHRA score class 3/4 (intermediate/frequent) versus 1/2 (never/occasional).
EHRA score as a categorical variable was statistically significantly associated with cardioversion therapy (OR, 1.22; 95% confidence interval [CI], 1.01-1.45; P=0.0398) and catheter-based ablation procedures (OR, 1.97; 95% CI, 1.44-2.69; P<0.0001); and it was inversely associated with adequate heart rate control (OR, 0.80; 95% CI, 0.70-0.92; P=0.0015) at follow-up. In 10-fold cross validation, the statistical significance of these interventions remained similar (Table S5 ). Of the symptoms investigated, a high symptom burden of palpitations was predictive of cardioversion therapy, ablation, and the presence of sinus rhythm at follow-up, and it was inversely correlated with adequate heart rate control. Statistical significance was more frequently achieved when assessed across all categories. Results for the unadjusted model are provided in Table S10 . 
Clinical Outcomes
The EHRA score was associated with heart failure incidence during 1 year (OR, 1.65; 95% CI, 1.16-2.34; P=0.0053) ( .0069) were associated with the incidence of heart failure. None of the EHRA score symptoms were predictive of major bleeding events. P values derived from 10-fold cross validation are provided in Table S6 . Results for the unadjusted model are provided in Table S10 . Tables S11 through S15 provide the multivariable adjusted results for EHRA score categories separately, with EHRA class 1 as the reference. Unadjusted models are presented in Tables S14 through S16.
Discussion Main Findings
In a contemporary cohort of patients with AF, the EHRA score and its different symptom dimensions were moderately correlated with commonly used measures of QoL in AF. The score was predictive of interventions to restore sinus rhythm. Among symptoms, only palpitations were consistently related to interventions and rhythm at 1 year. Although the score itself was not strongly related to outcomes, different symptom dimensions were specifically predictive of cardiovascular outcomes (ie, anxiety for stroke; chest pain for coronary events; and fatigue, dyspnea, and anxiety for incident heart failure).
Symptom burden and QoL
The EHRA score has been recommended to specifically quantify AF-related symptom burden. 3 It has been validated with a moderate correlation with the Atrial Fibrillation Effect on Quality-of-Life questionnaire. 4, 6 Prior studies reported a strong negative correlation between the EHRA class and QoL assessed by components of the EQ-5D. We can demonstrate a weak correlation of EHRA score or its different symptom dimensions with EQ-5D-5L. Generic QoL measures mirror general functioning and well-being. They may be confounded by general characteristics of patients with AF, such as age, and lack potentially treatable dimensions that are specific to AF. 10 No relevant association was shown for PACT-Q. This finding is plausible, because the PACT-Q was developed to assess expectations and treatment satisfaction with AF-related anticoagulation, 9 but not necessarily effects of AF on health-related well-being.
Symptoms in relation to interventions
In the European AF guidelines, the EHRA score is recommended to tailor treatment for symptoms. 11 In our cohort, the EHRA score was a strong predictor of cardioversion and catheter-based ablation procedures during a 1-year follow-up. A higher symptom burden has clearly been associated with ablation therapy. 4 The score is most widely used by electrophysiologists who are crucial in the decision process to initiate therapies to restore sinus rhythm. Among the different symptom dimensions of the EHRA score, palpitations were significantly predictive of interventions to restore sinus rhythm. In addition, they were correlated with the presence of sinus rhythm and, inversely, with heart rate control, at follow-up. Palpitations are a common symptom and fairly specific in the setting of AF. If a regular rhythm can be achieved, symptoms resolve, which may explain the predictive ability for rhythm control treatment. 4 Palpitations thus appear to be a trigger to search for ways to restore and maintain sinus rhythm. In patients with perceived irregular heartbeat, sinus rhythm was more frequently reached rather than heart rate control. The latter was inversely associated with palpitations. The largest reduction in symptom burden over 1 year also was demonstrated for palpitations. Thus, palpitations appear to receive high attention and are targeted as a marker of successful treatment. On the other hand, it needs to be considered that palpitations may be subject to least recall bias and may therefore show stronger associations than other EHRA score components. Other symptom dimensions were not consistently related to interventions and rhythm. Fatigue and dyspnea significantly improved after successful cardioversion and ablation therapies and could be considered as triggers for interventions to improve AF symptom burden. In our study, the overall symptom burden was high, which may be explained by the specific assessment of all EHRA symptom dimensions required by the protocol. There was a trend towards a lower symptom burden after 1 year, which may indicate the success of regular follow-up by a cardiologist for the reduction of symptoms, which is a major goal of AF treatment. In particular, we observed significant interactions for cardioversion and ablation therapy that were related to a reduced symptom burden. It is well known that AF-related therapy helps to improve symptom burden. [12] [13] [14] In a prior observational study, QoL in patients with newly diagnosed AF reached normal values under pharmacologic therapy and cardioversion. 15 In this context, our data also show that EHRA score symptoms are sensitive to changes related to AF management over 1 year, an important quality of symptom measurement scales.
Symptom burden and outcomes
In our sample, the overall symptom burden measured by the EHRA score showed an association with the incidence of Figure. Distribution of European Heart Rhythm Association score categories across the 6 symptom dimensions at baseline and after 1 year.
Percentages are provided for each category.
heart failure, but not with other cardiovascular outcomes. Our findings are in line with evidence from the literature. Symptomatic patients (EHRA score ≥2) did not show an increased risk of stroke, myocardial infarction, or mortality in the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation. 6 Asymptomatic individuals in the AFFIRM (Atrial Fibrillation Follow-Up Investigation of Rhythm Management) trial had a comparable prognosis after accounting for clinical confounders, 16 and asymptomatic subclinical AF carries a significant risk of thromboembolic events. 17 In other studies, hospitalizations have been reported to be more frequent in patients with symptoms, and they may have driven Odds ratios are provided for EHRA score category 3/4 vs 1/2. P values across all 4 categories are from logistic regression analyses, as implemented in SAS proc logistic. All models are adjusted for age, sex, country, body mass index, systolic blood pressure, hypertension, diabetes mellitus, smoking, heart failure, and history of myocardial infarction. EHRA indicates European Heart Rhythm Association.
associations with combined cardiovascular outcomes. 6, 18, 19 Symptoms per se, combined in the EHRA score, do not appear to be strongly predictive of adverse events. Therefore, in line with our data, overall symptom severity does not carry a high prognostic utility.
In contrast, specific symptoms of the EHRA score, which overlap with other cardiovascular disease entities, appear to be more relevant for prognosis. Chest pain was a comparatively uncommon symptom in the Prevention of Thromboembolic Events-European Registry in Atrial Fibrillation, but it was Odds ratios are provided for EHRA score category 3/4 vs 1/2 in a multivariable-adjusted model. P values across all 4 categories are from logistic regression analyses, as implemented in SAS proc logistic. Covariates are age, sex, country, body mass index, systolic blood pressure, hypertension, diabetes mellitus, smoking, heart failure, and history of myocardial infarction. Coronary events comprised acute coronary syndrome and coronary revascularization. The model for incident heart failure does not include adjustment for heart failure. EHRA indicates European Heart Rhythm Association; TIA, transient ischemic attack. strongly related to coronary events. The inverse association of anxiety with stroke is likely a spurious finding because of the comparatively small number of strokes. Prior cohort studies demonstrated an increased stroke risk in individuals with anxiety. 20 In patients with AF, anxiety may be related to better compliance and medication adherence, however we could not demonstrate clear evidence to prove these assumption in our data. Fatigue and dyspnea, classic symptoms of heart failure, were associated with incident disease. Thus, specific symptoms need to be taken into account seriously in clinical practice and may require targeted workup to possibly avoid disease complications.
Limitations
Inherent to registry data from different centers, bias attributable to enrollment decisions, quality of data collection, and follow-up may have been introduced, despite training of the participating cardiologists and central data management. In addition, the EHRA score calculation in practice often is more subjective, and it shows less measurement accuracy because we used the maximum severity achieved for any of the symptom dimensions, which resulted in a relatively high symptom burden and may slightly impair the comparability with common practice. Compared with a recent study, 21 the proportion of interventions (cardioversions or catheter-based ablation therapies) was small, which may indicate a slightly older and sicker patient sample with more permanent AF and may reduce the generalizability to younger patients. On the other hand, our large data set provides valuable insights into current symptom-related health care patterns, treatment decisions, and outcomes.
In conclusion, our prospective data in a contemporary cohort with AF show that the EHRA symptom score and its components are moderately related to QoL and health utility of cardioversion and ablation therapy, and they predict a higher proportion of sinus rhythm after 1 year. Although the EHRA score is not strongly related to outcomes, its specific components should be considered to assess patients' prognosis. Thus, the EHRA score or slight modifications of it appear to be useful for clinical workup, which needs to be proved in future trials.
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